MeSH term
Frequency | Condition_Probility | Dilatation, Pathologic | 2 | 20.0 |
Humans | 196 | 0.0 |
In Vitro | 2 | 0.0 |
*Larynx, Artificial | 2 | 100.0 |
Respiratory Mechanics | 2 | 11.0 |
Algorithms | 2 | 0.0 |
Dioxins/*adverse effects | 2 | 33.0 |
Reference Values | 7 | 0.0 |
Risk Assessment | 7 | 0.0 |
United States | 4 | 0.0 |
United States Environmental Protection Agency | 3 | 75.0 |
Animals | 46 | 0.0 |
Comparative Study | 26 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Infant, Newborn | 31 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Body Mass Index | 6 | 0.0 |
Female | 100 | 0.0 |
Heterozygote | 2 | 0.0 |
Middle Aged | 37 | 0.0 |
Receptors, Adrenergic, beta-3/*genetics | 2 | 10.0 |
Research Support, U.S. Gov't, P.H.S. | 49 | 0.0 |
Age Factors | 5 | 0.0 |
Aged | 26 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Body Composition | 16 | 6.0 |
Body Weight | 7 | 1.0 |
Energy Intake | 20 | 10.0 |
*Energy Metabolism | 25 | 26.0 |
Male | 94 | 0.0 |
*Obesity | 2 | 3.0 |
Research Support, Non-U.S. Gov't | 65 | 0.0 |
Weight Loss | 2 | 1.0 |
Adult | 79 | 0.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Esophagostomy | 2 | 100.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Blood Glucose/metabolism | 9 | 1.0 |
Dietary Fats/*administration & dosage | 3 | 3.0 |
Energy Metabolism | 10 | 5.0 |
Insulin/blood | 16 | 2.0 |
Postprandial Period | 3 | 3.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Drug Interactions | 4 | 0.0 |
Environmental Pollutants/*adverse effects | 2 | 16.0 |
Blotting, Northern | 4 | 0.0 |
Blotting, Western | 2 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Dimerization | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Kinetics | 4 | 0.0 |
Leucine Zippers | 2 | 1.0 |
Liver/metabolism | 3 | 0.0 |
Mice | 15 | 0.0 |
Models, Biological | 4 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Protein Binding | 5 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Time Factors | 15 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
*Nuclear Proteins | 6 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Transcription Factors/chemistry/*metabolism | 2 | 1.0 |
Tumor Cells, Cultured | 5 | 0.0 |
*Body Temperature | 2 | 7.0 |
Intubation, Intratracheal/adverse effects | 2 | 50.0 |
Surgical Flaps | 2 | 11.0 |
Tracheoesophageal Fistula/etiology/*surgery | 2 | 100.0 |
Aging/*metabolism | 2 | 0.0 |
Body Composition/physiology | 5 | 9.0 |
Body Weight/physiology | 3 | 4.0 |
Energy Metabolism/*physiology | 15 | 16.0 |
*Food | 16 | 17.0 |
Oxidation-Reduction | 9 | 0.0 |
Oxygen Consumption/physiology | 3 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
3T3 Cells | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Transcription Factors/*genetics | 6 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Gastrostomy | 3 | 75.0 |
Larynx/*abnormalities/surgery | 2 | 100.0 |
Child, Preschool | 8 | 0.0 |
Infant | 14 | 0.0 |
Retrospective Studies | 13 | 0.0 |
Calorimetry, Indirect | 8 | 15.0 |
Exercise/*physiology | 12 | 3.0 |
Predictive Value of Tests | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Carcinogens/*toxicity | 2 | 1.0 |
Environmental Pollutants/*toxicity | 2 | 5.0 |
Polychlorinated Biphenyls/*toxicity | 6 | 37.0 |
Biological Markers | 2 | 0.0 |
*Body Composition | 4 | 3.0 |
Postprandial Period/*physiology | 2 | 6.0 |
Base Sequence | 10 | 0.0 |
Binding Sites | 7 | 0.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Intubation, Intratracheal/*adverse effects | 2 | 40.0 |
Radiography, Thoracic | 2 | 5.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
*Tomography, X-Ray Computed | 2 | 2.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Muscle, Skeletal/metabolism | 3 | 1.0 |
*Transcription, Genetic | 3 | 0.0 |
Transfection | 3 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Child | 15 | 0.0 |
Esophageal Atresia/mortality/*surgery | 2 | 100.0 |
Prognosis | 7 | 0.0 |
Risk Factors | 6 | 0.0 |
Survival Analysis | 4 | 0.0 |
Adipose Tissue/*metabolism | 2 | 1.0 |
Analysis of Variance | 5 | 0.0 |
Basal Metabolism/*physiology | 3 | 37.0 |
Blood Glucose/analysis | 7 | 1.0 |
Body Temperature Regulation | 9 | 39.0 |
Calorimetry | 6 | 9.0 |
Adolescent | 20 | 0.0 |
Tracheoesophageal Fistula/*surgery | 5 | 100.0 |
Treatment Outcome | 12 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Diet | 6 | 1.0 |
*Basal Metabolism | 5 | 33.0 |
Cloning, Molecular | 5 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Basal Metabolism | 16 | 35.0 |
Dietary Carbohydrates/*administration & dosage | 3 | 12.0 |
Heart Rate | 3 | 1.0 |
Anastomosis, Surgical/methods | 2 | 50.0 |
Esophageal Atresia/complications/mortality/*surgery | 2 | 100.0 |
Evaluation Studies | 2 | 0.0 |
Follow-Up Studies | 13 | 0.0 |
Survival Rate | 4 | 0.0 |
Tracheoesophageal Fistula/complications/mortality/*surgery | 2 | 100.0 |
Reoperation | 2 | 1.0 |
Dioxins/*toxicity | 5 | 50.0 |
Rats | 10 | 0.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Risk Assessment/methods | 4 | 15.0 |
Cross-Over Studies | 2 | 0.0 |
Questionnaires | 3 | 0.0 |
*Circadian Rhythm | 4 | 1.0 |
Mice, Knockout | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Bronchoscopy | 2 | 3.0 |
English Abstract | 8 | 0.0 |
*Laryngectomy | 2 | 100.0 |
Receptors, Aryl Hydrocarbon/metabolism | 3 | 7.0 |
Exercise | 4 | 3.0 |
Food | 8 | 6.0 |
Oxygen Consumption | 8 | 3.0 |
Environmental Exposure | 3 | 2.0 |
Tetrachlorodibenzodioxin/*analogs & derivatives/toxicity | 2 | 100.0 |
Aging/*physiology | 4 | 1.0 |
Body Constitution | 2 | 1.0 |
Body Temperature Regulation/*physiology | 7 | 30.0 |
Eating/*physiology | 8 | 11.0 |
Milk, Human/*chemistry | 2 | 4.0 |
Structure-Activity Relationship | 3 | 0.0 |
Mice, Inbred C3H | 2 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Tracheotomy/adverse effects | 2 | 100.0 |
*Diseases in Twins | 2 | 6.0 |
*Body Temperature Regulation | 14 | 50.0 |
Dietary Carbohydrates/administration & dosage | 2 | 7.0 |
Dietary Fats/administration & dosage | 3 | 3.0 |
Dietary Proteins/administration & dosage | 3 | 8.0 |
Eating | 3 | 2.0 |
Cells, Cultured | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
*Infant, Premature | 2 | 3.0 |
Medical Records | 2 | 2.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Esophageal Atresia/*surgery | 5 | 100.0 |
Methods | 2 | 0.0 |
Organ Specificity | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
*Risk Assessment | 2 | 11.0 |
Tetrachlorodibenzodioxin/*toxicity | 3 | 6.0 |
Occupational Exposure | 3 | 3.0 |
Aging | 2 | 0.0 |
Insulin Resistance | 2 | 1.0 |
Postoperative Care | 2 | 2.0 |
Tracheoesophageal Fistula/*complications/diagnosis/surgery | 2 | 100.0 |
Eating/physiology | 5 | 9.0 |
Prospective Studies | 2 | 0.0 |
Incidence | 3 | 0.0 |
Diet, Reducing | 2 | 6.0 |
Food, Formulated | 2 | 6.0 |
Oxygen Consumption/*physiology | 2 | 6.0 |
Weight Loss/*physiology | 3 | 9.0 |
Feeding Behavior/*physiology | 3 | 10.0 |
Mutation | 2 | 0.0 |
Anastomosis, Surgical | 2 | 10.0 |
Body Temperature Regulation/physiology | 4 | 16.0 |
Energy Intake/physiology | 3 | 11.0 |
*Energy Intake | 4 | 11.0 |
Pedigree | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
*Weight Loss | 2 | 4.0 |
Doxorubicin | 2 | 33.0 |
Pregnancy | 10 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Hodgkin Disease/*complications/drug therapy | 2 | 100.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Body Temperature/*physiology | 3 | 37.0 |
Cell Line | 5 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Obesity/*metabolism | 4 | 5.0 |
Exercise Test | 2 | 0.0 |
Tracheoesophageal Fistula/etiology/*therapy | 2 | 100.0 |
Energy Metabolism/physiology | 5 | 8.0 |
Motor Activity/physiology | 3 | 4.0 |
Respiratory Function Tests | 3 | 1.0 |
*Diet, Reducing | 4 | 5.0 |
Energy Metabolism/*drug effects | 4 | 23.0 |
*Surgical Flaps | 2 | 14.0 |
Adipose Tissue/chemistry | 2 | 10.0 |
*Eating | 6 | 10.0 |
Body Temperature Regulation/*drug effects | 4 | 28.0 |
Restriction Mapping | 2 | 0.0 |
Chick Embryo | 2 | 0.0 |
Esophagoscopy | 2 | 6.0 |
Circadian Rhythm | 3 | 1.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Radiotherapy Dosage | 2 | 1.0 |
Oncogene Proteins, Viral/*genetics | 2 | 3.0 |
Obesity/*physiopathology | 6 | 10.0 |
Esophagus/surgery | 2 | 9.0 |
Epinephrine/blood | 4 | 3.0 |
Lipids/metabolism | 2 | 0.0 |
Respiration | 6 | 10.0 |
*Diet | 2 | 0.0 |
Basal Metabolism/physiology | 3 | 30.0 |
Fatty Acids/metabolism | 2 | 1.0 |
Dietary Carbohydrates/metabolism | 2 | 16.0 |
Norepinephrine/blood | 4 | 2.0 |
Sympathetic Nervous System/*physiology | 2 | 4.0 |
Physical Fitness | 2 | 8.0 |
Nitrogen/metabolism | 2 | 8.0 |
Tracheoesophageal Fistula/surgery | 2 | 100.0 |
Mathematics | 2 | 1.0 |
Food Contamination/*analysis | 2 | 13.0 |
*Exertion | 3 | 1.0 |
Recurrence | 2 | 0.0 |
Cell Transformation, Neoplastic/*drug effects | 2 | 5.0 |
*Body Weight | 2 | 3.0 |
Longitudinal Studies | 2 | 0.0 |
